170 related articles for article (PubMed ID: 22087283)
1. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Luo P; Lin M; Li L; Yang B; He Q
PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Dasmahapatra G; Lembersky D; Rahmani M; Kramer L; Friedberg J; Fisher RI; Dent P; Grant S
Cancer Biol Ther; 2009 May; 8(9):808-19. PubMed ID: 19270531
[TBL] [Abstract][Full Text] [Related]
5. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.
Di Francesco AM; Ubezio P; Torella AR; Meco D; Pierri F; Barone G; Cusano G; Pisano C; D'Incalci M; Riccardi R
Invest New Drugs; 2012 Aug; 30(4):1319-30. PubMed ID: 21633925
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.
Luo P; Lin M; Lin M; Zhu D; Wang Z; Shen J; Yang B; He Q
Pharmazie; 2010 Mar; 65(3):213-8. PubMed ID: 20383943
[TBL] [Abstract][Full Text] [Related]
8. All-trans retinoic acid arrests neuroblastoma cells in a dormant state. Subsequent nerve growth factor/brain-derived neurotrophic factor treatment adds modest benefit.
Cernaianu G; Brandmaier P; Scholz G; Ackermann OP; Alt R; Rothe K; Cross M; Witzigmann H; Tröbs RB
J Pediatr Surg; 2008 Jul; 43(7):1284-94. PubMed ID: 18639684
[TBL] [Abstract][Full Text] [Related]
9. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Yu C; Rahmani M; Dent P; Grant S
Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Nawrocki ST; Sweeney-Gotsch B; Takamori R; McConkey DJ
Mol Cancer Ther; 2004 Jan; 3(1):59-70. PubMed ID: 14749476
[TBL] [Abstract][Full Text] [Related]
11. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
[TBL] [Abstract][Full Text] [Related]
12. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
13. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
Du BY; Song W; Bai L; Shen Y; Miao SY; Wang LF
Chemotherapy; 2012; 58(1):44-51. PubMed ID: 22327308
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
17. Piling up the JNK: drug synergy through ER stress.
Hertan LM; Koumenis C
Cancer Biol Ther; 2009 May; 8(9):820-2. PubMed ID: 19458484
[No Abstract] [Full Text] [Related]
18. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
19. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
[TBL] [Abstract][Full Text] [Related]
20. [Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].
Fu BB; Fan Y; Hao LC; Liao AJ; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):671-5. PubMed ID: 21729547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
